Self-collection of vaginal samples for HPV testing to enhance cervical cancer prevention
NCI Cervical Cancer 'Last Mile' Initiative 'Self-Collection for HPV Testing to Improve Cervical Cancer Prevention' (SHIP) Trial
This study tests if women can accurately collect their own vaginal samples for HPV testing to help prevent cervical cancer, compared to samples collected by doctors.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 500 (estimated) |
| Ages | 25 Years and up |
| Sex | Female |
| Sponsor | National Cancer Institute (NCI) NIH |
| Locations | 25 sites (Birmingham, Alabama and 24 other locations) |
| Trial ID | NCT06611540 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of self-collected vaginal samples for HPV testing in patients referred for colposcopy and cervical excisional procedures. The study aims to determine the clinical accuracy of self-collected samples compared to clinician-collected samples in detecting cervical precancer and cancer. Participants will undergo both self-collection and clinician-collection of samples, followed by standard care procedures such as colposcopy and biopsies. The trial also explores factors affecting the usability and acceptability of self-collection methods.
Who should consider this trial
Good fit: Ideal candidates are women aged 25 and older who have been referred for colposcopy or cervical excisional procedures and have had recent HPV testing.
Not a fit: Patients who are pregnant or have had recent cervical treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could increase cervical cancer screening rates and early detection through more accessible self-collection methods.
How similar studies have performed: Other studies have shown promise in using self-collection methods for HPV testing, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Willingness and ability to provide a documented informed consent. * Is 25 years or older. * Has an intact cervix. * Has had a referral for colposcopy and/or cervical excisional procedure in which routine cervical cancer screening has included HPV testing (HPV primary screening, co-testing, or atypical squamous cells of undetermined significance \[ASC-US\] cytology triage) or abnormal cytology performed within the past 12 months preceding the referral visit. * Willing and able to undergo colposcopy, and if clinically indicated for SOC purposes, a biopsy, endocervical curettage, and/or a cervical excisional procedure, as applicable. Exclusion Criteria: * Is pregnant when presenting for the referral visit or gave birth within the past 3 months. * Has a known history of excisional or ablative therapy to the cervix (e.g., loop electrosurgical excision procedure \[LEEP\], cone biopsy, cervical laser surgery, cryotherapy, thermal ablation) in the last 12 months prior to the referral visit. * Has had a complete or partial hysterectomy, either supracervical or involving removal of the cervix, via self-report or confirmation via medical records. * Known medical conditions that, in the opinion of the investigator, preclude study participation. * Previous participation in the SHIP Trial. Participation is defined as completing the self-collection. * Is experiencing unusual bleeding or pelvic pain.
Where this trial is running
Birmingham, Alabama and 24 other locations
- University of Alabama at Birmingham Cancer Center — Birmingham, Alabama, United States (Not_yet_recruiting)
- UCSF Medical Center-Parnassus — San Francisco, California, United States (Not_yet_recruiting)
- Yale University — New Haven, Connecticut, United States (Not_yet_recruiting)
- University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida, United States (Not_yet_recruiting)
- Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia, United States (Not_yet_recruiting)
- UofL Health Medical Center Northeast — Louisville, Kentucky, United States (Not_yet_recruiting)
- Louisiana State University Health Science Center — New Orleans, Louisiana, United States (Not_yet_recruiting)
- Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland, United States (Not_yet_recruiting)
- University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States (Recruiting)
- Minneapolis VA Medical Center — Minneapolis, Minnesota, United States (Recruiting)
- University of Mississippi Medical Center — Jackson, Mississippi, United States (Not_yet_recruiting)
- University of New Mexico Cancer Center — Albuquerque, New Mexico, United States (Recruiting)
- Montefiore Medical Center-Einstein Campus — Bronx, New York, United States (Not_yet_recruiting)
- NYP/Weill Cornell Medical Center — New York, New York, United States (Not_yet_recruiting)
- UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina, United States (Recruiting)
- University of Cincinnati Cancer Center-UC Medical Center — Cincinnati, Ohio, United States (Not_yet_recruiting)
- Cleveland Clinic Foundation — Cleveland, Ohio, United States (Not_yet_recruiting)
- University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma, United States (Not_yet_recruiting)
- University of Pennsylvania/Abramson Cancer Center — Philadelphia, Pennsylvania, United States (Recruiting)
- UPMC-Magee Womens Hospital — Pittsburgh, Pennsylvania, United States (Not_yet_recruiting)
- M D Anderson Cancer Center — Houston, Texas, United States (Not_yet_recruiting)
- Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah, United States (Recruiting)
- Virginia Commonwealth University/Massey Cancer Center — Richmond, Virginia, United States (Not_yet_recruiting)
- University of Washington Medical Center - Northwest — Seattle, Washington, United States (Not_yet_recruiting)
- University of Puerto Rico — San Juan, Puerto Rico (Not_yet_recruiting)
Study contacts
- Principal investigator: Vikrant V Sahasrabuddhe — National Cancer Institute Division of Cancer Prevention
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.